Hepatitis C testing for people who inject drugs in the United Kingdom: Why is uptake so low?

Drugs: Education, Prevention and Policy

Volumn 21, Issue 4, 2014, Pages 333-342

  Harris, Magdalena ^a   McDonald, Bethan ^a   Rhodes, Tim ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84905497453     PISSN: 09687637     EISSN: 14653370     Source Type: Journal    
DOI: 10.3109/09687637.2014.899988     Document Type: Article

References (43)

1. Aitken, C.K., Kerger, M., and Crofts, N. (2002). Peer-delivered hepatitis C testing and counselling: A means of improving the health of injecting drug users. Drug and Alcohol Review, 21, 33-37.
2. Car, J., Gurol-Urganci, I., de Jongh, T., Vodopivec-Jamsek, V., and Atun, R. (2012). Mobile phone messaging reminders for attendance at healthcare appointments. Cochrane Database of Systematic Reviews, 7, CD007458.
3. Craine, N., Parry, J., OToole, J., DArcy, S., and Lyons, M. (2009). Improving blood-borne viral diagnosis; clinical audit of the uptake of dried blood spot testing offered by a substance misuse service. Journal of Viral Hepatitis, 16, 219-222.
4. Craine, N., Walker, M., Carnwath, T., and Klee, H. (2004). Hepatitis C testing and injecting risk behaviour: The results of a UK based pilot study. The International Journal of Drug Policy, 15, 115-122.
5. Day, C.A., White, B., Thein, H.H., Doab, A., Dore, G.J., Bates, A., Maher, L. (2008). Experience of hepatitis C testing among injecting drug users in Sydney, Australia. AIDS Care, 20, 116-123.
6. Department of Health. (2007). Drug Misuse and Dependence: UK Guidelines on Clinical Management. London: Department of Health (England), the Scottish Government, Welsh Assembly Government and Northern Ireland Executive.
7. European Association for Study of the Liver: EASL Clinical Practice Guidelines. (2011). Management of hepatitis C virus infection. Journal of Hepatology, 55, 245-264.
8. Glaser, B.G., and Strauss, A.L. (1967). The discovery of grounded theory: Strategies for qualitative research. Chicago, IL: Aldine.
9. Harris, M., and Rhodes, T. (2012). Venous access and care: Harnessing pragmatics in harm reduction for people who inject drugs. Addiction, 107, 1090-1096.
10. Harris, M., and Rhodes, T. (2013). Injecting practices in sexual partnerships: HCV transmission potentials in a risk equivalence framework. Drug and Alcohol Dependence, 3, 617-623.
11. Harris, M., Rhodes, T., and Martin, A. (2013). Taming systems to create enabling environments for HCV treatment: Negotiating trust in the drug and alcohol setting. Social Science and Medicine, 83, 19-26.
12. Hatzakis, A., Wait, S., Bruix, J., Buti, M., Carballo, M., Cavaleri, M., Esmat, G. (2011). The state of hepatitis B and C in Europe: Report from the hepatitis B and C summit conference. Journal of Viral Hepatitis, 18, 1-16.
13. Health Protection Agency: Hepatitis C in the UK: 2012 Report. Health Protection Agency 2012.
14. Hickman, M., McDonald, T., Judd, A., Nichols, T., Hope, V., Skidmore, S., and Parry, J.V. (2008). Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: A cluster randomized controlled trial. Journal of Viral Hepatitis, 15, 250-254.
15. Iversen, J., and Maher, L. (2012). Australian Needle and Syringe Program National Data Report 2007-2011. Sydney: The Kirby Institute, University of New South Wales.
16. Khaw, F.M., Stobbart, L., and Murtagh, M.J. (2007). I just keep thinking I havent got it because Im not yellow: A qualitative study of the factors that influence the uptake of Hepatitis C testing by prisoners. BMC Public Health, 7, 98.
17. Kirwan, P., Evans, B., and Brant, L. (2011). Hepatitis C and B testing in English prisons is low but increasing. Journal of Public Health, 33, 197-204.
18. Lally, M.A., Montstream-Quas, S.A., Tanaka, S., Tedeschi, S.K., and Morrow, K.M. (2008). A qualitative study among injection drug using women in Rhode Island: Attitudes toward testing, treatment, and vaccination for hepatitis and HIV. AIDS Patient Care and STDs, 22, 53-64.
19. Lazarus, J.V., Shete, P.B., Eramova, I., Merkinaite, S., and Matic, S. (2007). HIV/hepatitis coinfection in eastern Europe and new pan-European approaches to hepatitis prevention and management. International Journal of Drug Policy, 18, 426-432.
20. Lim, E.J., Haar, J., and Morgan, J. (2008). Can text messaging results reduce time to treatment of Chlamydia trachomatis? Sexually Transmitted Infections, 84, 563-564.
21. Martin, N.K., Vickerman, P., Foster, G.R., Hutchinson, S.J., Goldberg, D.J., and Hickman, M. (2011). Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. Journal of Hepatology, 54, 1137-1144.
22. Mason, S., Watts, A., Sheils, S., and Koorey, D. (2007). Improving access to HCV treatment: External jugular venepuncture can overcome problems with difficult venous access. The International Journal of Drug Policy, 18, 433-436.
23. National Institute for Clinical Excellence: Technology Appraisal Guidance 75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic HCV. London: National Institute for Clinical Excellence; 2004.
24. National Institute for Health and Clinical Excellence. Drug misuse: Psychosocial interventions. National Institute for Health and Clinical Excellence; 2007.
25. Nelson, P.K., Mathers, B.M., Cowie, B., Hagan, H., Des Jarlais, D., Horyniak, D., and Degenhardt, L. (2011). Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews. The Lancet, 378, 571-583.
26. Paterson, B.L., Backmund, M., Hirsch, G., and Yim, C. (2007). The depiction of stigmatization in research about hepatitis C. International Journal of Drug Policy, 18, 364-373.
27. Petry, N.M. (2006). Contingency management treatments. The British Journal of Psychiatry, 189, 97-98.
28. Philpott, A., Knerr, W., and Boydell, V. (2006). Pleasure and prevention: When good sex is safer sex. Reproductive Health Matters, 14, 23-31.
29. Race, K. (2008). The use of pleasure in harm reduction: Perspectives from the history of sexuality. The International Journal of Drug Policy, 19, 417-423.
30. Radcliffe, P., and Stevens, A. (2008). Are drug treatment services only for thieving junkie scumbags? Drug users and the management of stigmatised identities. Social Science and Medicine, 67, 1065-1073.
31. Rhodes, T., and Coomber, R. (2010). Qualitative methods and theory in addictions research. In P.G. Miller, J. Strang, and P.M. Miller (Eds.), Addiction research methods (pp. 59-78). Oxford: Blackwell.
32. Rhodes, T., Davis, M., and Judd, A. (2004). Hepatitis C and its risk management among drug injectors in London: Renewing harm reduction in the context of uncertainty. Addiction, 99, 621-633.
33. Richards, M. (2010). Extent and causes of international variations in drug usage. London: Department of Health.
34. Semer, N., Ellison, J., Mansell, C., Hoika, L., MacDougall, W., Gansky, S.A., and Walsh, M.M. (2005). Development and evaluation of a tobacco cessation motivational program for adolescents based on physical attractiveness and oral health. Journal of Dental Hygiene, 79, 9.
35. Siedner, M.J., Haberer, J.E., Bwana, M.B., Ware, N.C., and Bangsberg, D.R. (2012). High acceptability for cell phone text messages to improve communication of laboratory results with HIV-infected patients in rural Uganda: A crosssectional survey study. BMC Medical Informatics and Decision Making, 12, 56.
36. Strang, J., Keaney, F., Butterworth, G., Noble, A., and Best, D. (2001). Different forms of heroin and their relationship to cook-up techniques: Data on, and explanation of, use of lemon juice and other acids. Substance Use and Misuse, 36, 573-588.
37. Strauss, S., Munoz-Plaza, C.E., Tiburcio, N.J., Astone- Twerell, J., Des Jarlais, D.C., Gwadz, M., Rosenblum, A. (2008). Barriers and facilitators to undergoing Hepatitis C virus (HCV) testing through drug treatment programs. Journal of Drug Issues, 38, 1161-1185.
38. Swan, D., Long, J., Carr, O., Flanagan, J., Irish, H., Keating, S., McKiernan, S. (2010). Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: A qualitative exploration.
39. Treloar, C.J., Hopwood, M.N., and Loveday, S.K. (2002). Hepatitis C-related discrimination in healthcare. Report of the Third Australasian Conference on Hepatitis C, Melbourne, March 202. The Medical Journal of Australia, 177, 233-234.
40. Tripathi, A., Duffus, W.A., Kissinger, P., Brown, T.J., Gibson, J.J., and Mena, L.A. (2012). Delivering laboratory results by text message and e-mail: A survey of factors associated with conceptual acceptability among STD clinic attendees. Telemedicine Journal and E-Health, 18, 500-506.
41. White, B., Day, C., Thein, H.H., Doab, A., Bates, A., Holden, J., Maher, L. (2008). Acceptability of hepatitis C virus testing methods among injecting drug users. Drug and Alcohol Review, 27, 666-670.
42. Winter, R., Nguyen, O., Higgs, P., Armstrong, S., Duong, D., Thach, M.L., Hellard, M. (2008). Integrating enhanced hepatitis C testing and counselling in research. The International Journal of Drug Policy, 19, 66-70.
43. World Health Organisation Regional Office for Europe: Barriers and facilitators to hepatitis C treatment for people who inject drugs: A qualitative study. Copenhagen: World Health Organisation Regional Office for Europe; 2012.